Clinical Trials Browser

Has announcements × Genitourinary × 30 days × Clear all

Prostatic Neoplasms

NCT02365597 2026-04-13

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 2 FDA

Genitourinary

Urothelial Cancer

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02489318 2026-04-13

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 2 FDA

Genitourinary

Prostatic Neoplasms

NCT03390504 2026-04-13

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT03748641 2026-04-13

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 2 FDA

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 3 FDA

Genitourinary

Metastatic Castration-sensitive Prostate Cancer

NCT04640623 2026-04-13

SunRISe-1

Phase 2 Active not recruiting

220 enrolled 3 FDA

Genitourinary

Urinary Bladder Neoplasms

NCT02650401 2026-03-25

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 2 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT03288545 2026-03-24